氟骨三醇 | 83805-11-2

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 氟骨三醇
• 英文名称: Falecalcitriol
• 英文别名: 1α,25-dihydroxy-26,26,26,27,27,27-hexafluorovitamin D₃；ST-630；Fulstan；Horner；26,26,26,27,27,27-hexafluoro-1α,25-dihydroxycholecalciferol；(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-7,7,7-trifluoro-6-hydroxy-6-(trifluoromethyl)heptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
• CAS: 83805-11-2
• 化学式: C₂₇H₃₈F₆O₃
• 分子量: 524.587
• InChiKey: XPYGGHVSFMUHLH-UUSULHAXSA-N

物化性质

• 沸点：
  576.9±50.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  9

安全信息

• 储存条件：
  2-8℃

制备方法与用途

优点

氟骨三醇的作用效果比骨化三醇以及其他维生素D类药物更好，且不会产生持续性的高钙血症和高磷血症。

用途

氟骨三醇适用于骨质疏松患者、银屑病以及肾透析患者的甲状旁腺功能亢进症的治疗。

生物活性

Falecalcitriol（Fulstan；Hornel）是骨化三醇的一种类似物，在体内具有更高且更持久的生物活性。

反应信息

• 作为反应物：
  描述：

  氟骨三醇 在 戴斯-马丁氧化剂 作用下， 以 乙腈 为溶剂， 反应 4.0h， 以66%的产率得到(6Z)-(3R)-26,26,26,27,27,27-hexafluoro-9,10-seco-5(10),6,8-cholestatriene-3,25-diol-1-one
  参考文献：
  名称：

  Synthesis and biological evaluations of A-ring isomers of 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitamin D 3

  摘要：

  The activated vitamin D-3 derivative 26,27-F-6-1 alpha,25(OH)(2)D-3 (2a), its three A-ring diastereomers (2b, 2c, 2d), and 5,6-trans isomer (2e) were prepared. Two analogues (2b, 2c) of these isomers were synthesized by a palladium catalyzed coupling reaction using Vinyl bromide 5 and enynes (6a, 6b), which were derived from readily commercially available 2S-(+)-glycidyl p-toluenesulfonate 7, as a common starting material. Competitive vitamin D receptor (VDR) binding affinities of these diastereomers of 2a were evaluated. Interestingly, the stereochemical effects at C-1,3 of 2a were considerably more moderate than those of 1 alpha,25(OH)(2)D-3 (1). In particular, isomerization at the 5,6-double bond of 2a only slightly reduced VDR affinity, whereas 5,6-trans-1 alpha,25(OH)(2)D-3 had a significantly lower binding affinity than 1. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00142-5
• 作为产物：
  描述：

  (1S,3R,8S,9S,10R,13R,14S,17R)-17-[(2R)-5-(benzenesulfonyl)pentan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-1,3-diol 在 4-二甲氨基吡啶 盐酸 、 氢氧化钾 、 disodium hydrogenphosphate 、 正丁基锂 、 sodium amalgam 、 三乙胺 、 二异丙胺 作用下， 以 四氢呋喃 、 吡啶 、 甲醇 、 乙二醇二甲醚 为溶剂， 反应 53.34h， 生成 氟骨三醇
  参考文献：
  名称：

  Studies on organic fluorine compounds. XXXIX. Studies on steroids. LXXIX. Synthesis of 1.ALPHA.,25-dihydroxy-26,26,26,27,27,27-hexafluorovitamin D3.

  摘要：

  1α, 25-二羟基-26, 26, 26, 27, 27, 27-六氟胆固醇通过两种方法合成。胆酸首先转化为1α-羟基-24-砜衍生物，然后与六氟丙酮和锂化的24-砜反应。随后去除砜基团得到六氟-1α, 25-二羟基化合物。另一种方法是在侧链上构建六氟-25-羟基部分，然后引入1α位置的羟基。六氟衍生物通过相应的5, 7-二烯转化为维生素D形式，即1α, 25-二羟基六氟维生素D3。

  DOI：

  10.1248/cpb.30.4297

文献信息

• Drugs for diabetes
  申请人：——

  公开号：US20040023890A1

  公开（公告）日：2004-02-05

  Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B) b0 —(C) c0 —NO 2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking group wherein the precursor must meet the tests described in the application, C is a a bivalent linking group as defined in the invention.

  用于治疗糖尿病的化合物或其盐，具有如下通用公式（I）：A-(B) b0 —(C) c0 —NO 2 其中A含有具有抗炎或镇痛活性的药物的自由基，B是一个双价连接基团，其中前体必须符合本申请中描述的测试，C是如发明中定义的双价连接基团。
• Hydroxylated nebivolol metabolites
  申请人：O'Donnell P. John

  公开号：US20070014733A1

  公开（公告）日：2007-01-18

  Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration. This invention provides hydroxylated nebivolol metabolites and compositions comprising nebivolol and/or at least one hydroxylated metabolite of nebivolol and/or at least one additional compound used to treat cardiovascular diseases or a pharmaceutically acceptable salt thereof. In addition, this invention provides methods of treating and/or preventing vascular diseases by administering at least one hydroxylated metabolite of nebivolol that is capable of releasing a therapeutically effective amount of nitric oxide to a targeted site affected by the vascular disease. Also, this invention is directed to the treatment and/or prevention of migraine headaches administering at least one hydroxylated metabolite of nebivolol. This invention may also be used in conjunction with or as a single treatment of metabolic syndrome disorders.

  羟基化奈必洛尔代谢物在急性给药后以浓度依赖性方式增加人内皮细胞制剂的一氧化氮释放。此外，羟基化奈必洛尔代谢物，包括但不限于4-羟基-6,6'-二氟代-、4-羟基-5-苯酚-6,6'-二氟代-和4-羟基-8-苯并-6,6'-二氟代-，在慢性给药后能够增加人内皮细胞的一氧化氮释放能力。本发明提供了羟基化奈必洛尔代谢物和包含奈必洛尔和/或至少一种羟基化奈必洛尔代谢物和/或至少一种用于治疗心血管疾病的附加化合物的组合物，以及可药用的盐。此外，本发明还提供了通过给药至少一种能够释放治疗有效量的一氧化氮到受血管疾病影响的靶向部位的羟基化奈必洛尔代谢物来治疗和/或预防血管疾病的方法。本发明还涉及通过给药至少一种羟基化奈必洛尔代谢物来治疗和/或预防偏头痛。本发明还可以与治疗代谢综合征障碍的其他治疗联合使用，或作为单一治疗。
• [EN] VITAMIN D ANALOGUES, COMPOSITIONS COMPRISING SAID ANALOGUES AND THEIR USE<br/>[FR] ANALOGUES DE LA VITAMINE D, COMPOSITIONS COMPRENANT LESDITS ANALOGUES ET LEUR UTILISATION
  申请人：LEO PHARMA AS

  公开号：WO2004037781A1

  公开（公告）日：2004-05-06

  Compounds according to formula I: in which formula R1 and R2, which may be the same or different, represent halogen, (C1-C6) hydrocarbyl, optionally substituted with one or two hydroxyl group on one or more fluorine atoms, or, together with the carbon atom to which they are both attached, R1 and R2 form a (C3-C6)carbocyclic ring, or one of R1 and R2 taken together with R3 forms a direct bond, such that a triple bond is constituted, or R1 and R2 represent both hydrogen; R3 when not forming a direct bond with one of R1 and R2 represents hydrogen or (C1-C3)hydrocarbyl; X represents (E)-ethylene, (Z)-ethylene, ethynylene, or a bond; Y and Z independently represent hydrogen or methyl; the bond between C#16 and C#17 is depicted with a dotted line to illustrate that said bond may be either a single bond, in which case the projection of the ring substituents is beta, or a double bond; A represents hydroxyl, fluorine or hydrogen; B represents CH2 or H2; the configuration is the 3-position corresponds to the same configuration as in natural vitamine D3 (normal), or the configuration in the configuration in the 3-position is opposite to that of natural vitamin D3(epi); with the proviso that when X represents (E)-ethylene or (Z)-ethylene, one of R1 and R2 taken together with R3 may not form a direct bond, such that a triple bond is constituted; with the further proviso that when X represents a bond R1 ands R2 are nor hydrogen; with the further proviso that the compound of formula I is not 3(S)-hyroxy-9, 10-secocholesta-5(Z),7(E),10(19),22(E),24-penta-ene; and prodrugs and stereo isomeric forms thereof are provided together with their use in therapy, and their use in the manufacture of medicaments.

  根据公式I：其中公式中的R1和R2，可以相同也可以不同，代表卤素，(C1-C6)烃基，可选地在一个或多个氟原子上用一个或两个羟基取代，或者，与它们都连接的碳原子一起，R1和R2形成一个(C3-C6)碳环，或者R1和R2中的一个与R3一起形成直接键，从而构成三键，或者R1和R2都代表氢；当R3不与R1和R2中的一个形成直接键时，代表氢或(C1-C3)烃基；X代表(E)-乙烯，(Z)-乙烯，乙炔基，或者一个键；Y和Z独立地代表氢或甲基；C#16和C#17之间的键用虚线表示，以说明该键可以是单键，此时环取代基的投影为β，或者是双键；A代表羟基，氟或氢；B代表CH2或H2；3位的构型与天然维生素D3 (正常)中的构型相对应，或者3位的构型与天然维生素D3 (epi)中的构型相反；但是当X代表(E)-乙烯或(Z)-乙烯时，R1和R2中的一个与R3一起不能形成直接键，从而构成三键；进一步的条件是，当X代表一个键时，R1和R2不是氢；进一步的条件是，公式I的化合物不是3(S)-羟基-9,10-去甲胆骨化甾-5(Z),7(E),10(19),22(E),24-五烯；还提供了它们的前药和立体异构体形式，以及它们在治疗中的用途，以及它们在药物制造中的用途。
• Methods and compositions for treating pain
  申请人：Moran M. Magdalene

  公开号：US20070219222A1

  公开（公告）日：2007-09-20

  The present application relates to compounds and methods for treating pain, incontinence and other conditions.

  本申请涉及化合物和治疗疼痛、失禁和其他疾病的方法。
• [EN] USE OF VITAMIN D COMPOUNDS FOR THE PREVENTION OR TREATMENT OF CHRONIC PROSTATITIS<br/>[FR] UTILISATION DE COMPOSES DE VITAMINE D POUR LA PREVENTION OU LE TRAITEMENT DE LA PROSTATITE CHRONIQUE
  申请人：BIOXELL SPA

  公开号：WO2006035075A1

  公开（公告）日：2006-04-06

  The use of a vitamin D compound in the prevention or treatment of chronic prostatitis and related methods, pharmaceutical formulations and kits.

  维生素D化合物在慢性前列腺炎的预防或治疗中的使用，以及相关方法、药物配方和工具包。